Meloxicam Tablet
Product Images NDC 50268-525

9 FDA label images from Avpak · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 50268-525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Table 1a)

1 (Table 1a)
Table presenting adverse events occurring in 2% or more of patients treated with Meloxicam (7.5 mg and 15 mg daily), placebo, or Diclofenac (100 mg daily) in a 12-week osteoarthritis clinical trial. It includes event categories such as gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin, with respective incidence percentages for each treatment group.*
FDA Label Image

1 (Table 1b)

1 (Table 1b)
Table presenting adverse events occurring in 2% or more of Meloxicam patients in two 12-week rheumatoid arthritis placebo-controlled trials. It compares the percentage of patients experiencing various disorders and symptoms across placebo, Meloxicam 7.5 mg daily, and Meloxicam 15 mg daily groups, showing data on gastrointestinal, general, infection, musculoskeletal, nervous system, and skin disorders.*
FDA Label Image

1 (Table 2)

1 (Table 2)
A data table presenting adverse event percentages occurring in 2% or more of Meloxicam patients during 4 to 6 weeks and 6 month active-controlled osteoarthritis trials. It compares Meloxicam 7.5 mg daily and 15 mg daily doses across categories including gastrointestinal, body as a whole, central and peripheral nervous system, and hematologic events.*
FDA Label Image

1 (Table 2b)

1 (Table 2b)
A data table listing various adverse events by system organ class, including musculoskeletal, psychiatric, respiratory, skin, and urinary categories. The table presents numerical values corresponding to specific symptoms such as arthralgia, insomnia, coughing, pruritus, and urinary tract infection, with footnotes explaining terms like edema and rash according to WHO preferred terms.*
FDA Label Image

1 (Adverse Reactions List)

1 (Adverse Reactions List)
A table listing adverse reactions grouped by body system for Meloxicam tablets, including cardiovascular issues like angina pectoris; central nervous system effects such as convulsions; gastrointestinal problems like ulcers and hemorrhage; and other system-specific reactions including arrhythmia, leukopenia, hepatic enzyme increases, dehydration, psychiatric symptoms, respiratory difficulties, skin and appendage reactions, sensory abnormalities, and urinary system impairments.*
FDA Label Image

1 (Table 3)

1 (Table 3)
A data table titled 'Table 3 Clinically Significant Drug Interactions with Meloxicam' detailing drugs that interfere with hemostasis. It lists drugs like anticoagulants, aspirin, ACE inhibitors, beta-blockers, diuretics, lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed, with columns describing their clinical impact and recommended intervention when used with meloxicam.*
FDA Label Image

Structural Formula (Mel01 0002 01)

Structural Formula (Mel01 0002 01)
Chemical structure of Meloxicam, depicting its molecular framework with rings, functional groups including hydroxy, carbonyl, sulfonamide, and a thiazole ring containing sulfur and nitrogen atoms.*
FDA Label Image

1 (525 15)

1 (525 15)
Meloxicam Tablets, USP 7.5 mg oral tablets in unit dose packaging, 50 tablets (5 x 10) by AvPAK. The label includes dosage strength, Rx only designation, a barcode, dispenser attention statement, storage instructions, manufacturer information, and a QR code.*
FDA Label Image

1 (526 15)

1 (526 15)
Meloxicam Tablets, USP 15 mg oral tablets in a package label showing two identical sections. Each section indicates 50 tablets (5 x 10) per unit dose, Rx only, with NDC 50268-526-15. The label includes storage instructions, dispensing warnings, and manufacturer information for AvPAK, Pulaski, TN, with a barcode and QR code visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.